GUTS Stock Forecast & Price Target

Fractyl Health is supported by Revita’s emerging durability profile, with REVEAL-1 showing a mean 5.3% total body weight change at one year, 78% retention of drug-induced weight loss, and 33% of participants still losing weight after a single procedure. The company’s outlook is further strengthened by mechanistic and procedural validation, including a statistically significant ablation-length dose response, a mean/median ablation length of 16 cm in the >300-patient pivotal cohort, and favorable safety feedback that keeps a potential De Novo path in view. In parallel, RAPID could compress reimbursement timing to around 2 months, while cash runway into early 2027 and RJVA-001’s advancement in the Netherlands provide additional funding and pipeline support.

Fractyl Health is a highly speculative clinical-stage company whose value depends heavily on unproven assets, with current valuation tied mainly to Revita under a 60% PoS assumption and full contribution, leaving limited margin for error. The stock faces material downside if trials are failed or inconclusive, if Rejuva does not advance as hoped, or if the company cannot secure adequate funding and is forced into dilutive capital raises. Additional risk comes from uncertain commercialization economics, including market penetration, expansion into other geographies, and pricing/bundling visibility, alongside the possibility of delisting for exchange noncompliance.